Lenident

Procaine Hydrochloride, the active ingredient in Lenident, is a local anesthetic presented as a dental solution for topical use. It provides reversible loss of sensation for dental procedures and oral mucosal applications in patients requiring local anesthesia. The formulation is intended for single‑use application by qualified dental professionals to achieve rapid onset of anesthesia.

GNH USA supplies Lenident as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and ensures compliance with EU regulations for pharmaceutical exports.

Lenident, a dental local anesthetic, acts on peripheral nerves to provide temporary loss of sensation during oral procedures.

- Dental extractions: enables painless removal of teeth by blocking nerve transmission. - Periodontal surgery: provides anesthesia for gum tissue manipulation. - Topical oral procedures: numbs the oral mucosa for minor interventions such as scaling or biopsy. - Root canal therapy: facilitates pain‑free instrumentation of the root canal system. - Dental implant placement: offers local anesthesia during osteotomy and implant insertion.

Adverse reactions to Lenident are generally related to its local anaesthetic properties and occasional hypersensitivity.

Common Side Effects: - Mild burning or stinging at the application site - Transient redness or swelling of the mucosa - Light‑headedness or dizziness - Nausea

Serious or Rare Side Effects: - Allergic reaction including rash, itching, or swelling - Anaphylaxis, a severe, potentially life‑threatening hypersensitivity - Methemoglobinemia, characterized by reduced oxygen‑carrying capacity of blood - Cardiac arrhythmias or seizures in cases of systemic absorption

When using Lenident, clinicians should observe several precautionary measures to minimise risk.

- Allergy assessment: verify the patient has no known hypersensitivity to procaine or related ester‑type anesthetics. - Cardiovascular monitoring: use caution in patients with significant heart disease, as systemic absorption may affect cardiac conduction. - Dosage limitation: adhere to recommended maximum single‑dose limits to avoid toxic plasma concentrations. - Concurrent medications: review concomitant drugs that may potentiate cardiac or CNS effects. - Special populations: exercise care in patients with hepatic impairment, as metabolism may be reduced. - Store at ambient temperature: keep in the original container, protect from light and moisture, and discard after the expiry date.

Lenident may interact with other medicines; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can increase the risk of severe hypotension and cardiac effects. - Class I antiarrhythmic agents (e.g., quinidine, procainamide): combined use may potentiate cardiotoxicity. - High‑dose epinephrine: may enhance systemic toxicity of procaine.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): local anesthetic infiltration may increase bleeding tendency. - Beta‑blockers: may augment bradycardia or hypotensive responses. - Central nervous system depressants (e.g., benzodiazepines, opioids): may increase sedation when systemic absorption occurs.